BioSpace News Archive

Zynerba Pharmaceuticals, Inc. presented data from the Phase 2 BRIGHT trial describing tolerability and efficacy of Zygel in children and adolescents with autism spectrum disorder over a longer term, 38-week treatment period.

Clene Inc. (NASDAQ: CLNN) along with its subsidiaries “Clene” and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company dedicated to the treatment of neurodegenerative disease using nanotechnology to treat cellular energetic failure, announced the final patient visit has been completed in its Phase 2 RESCUE-ALS study and that trial close-out activities have begun.

SOPHiA GENETICS SA (NASDAQ: SOPH), today reported financial results for the three months ended June 30, 2021.

NuVasive, Inc. (NASDAQ: NUVA), today announced the NuVasive Simplify® Cervical Disc one-level U.S. Food and Drug Administration (FDA) Investigational Device Exemption (IDE) study data was recently published in the International Journal of Spine Surgery.

Alkermes plc announced that it will begin accepting applications for its annual Alkermes Pathways Research Awards® program on Sept. 13, 2021.

Gemini Therapeutics, Inc. (Nasdaq: GMTX), today announced that Raj Maturi, M.D., Adjunct Clinical Assistant Professor of Ophthalmology at Indiana University School of Medicine and an investigator in the ReGAtta study, presented Gemini’s previously released initial results from its ongoing Phase 2a study at EURETINA 2021 Virtual held from September 9-12, 2021.

4D pharma plc today announces that 4D pharma management will present at the following virtual investor conferences: H.C. Wainwright 23rd Annual Global Investment Conference at 07:00 ET (12:00 BST) on Monday, September 13, 2021

iECURE to License Precision’s PCSK9-Directed ARCUS Nuclease and Pursue Four Gene Insertion Programs Focused on Liver Diseases; Precision Retains Rights Across All Indications Except Those Licensed to iECURE

Can-Fite BioPharma Ltd . today announced the Company’s CEO Dr. Pnina Fishman will present at the H.C. Wainwright 23rd Annual Global Investment Conference which will take place virtually on September 13 – 15, 2021.

Edesa Biotech, Inc. announced today that Dr. Par Nijhawan, Chief Executive Officer, will present at the H.C. Wainwright 23rd Annual Global Investment Conference being held virtually from September 13 to 15, 2021.